Loading stock data…
Baxter International Inc (BAX)
$22.40+0.73 (+3.37%)
Market ClosedLast close Jul 24
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Baxter International Inc. in the Healthcare sector is trading at $22.40 with a market capitalization of $10.8B. Wall Street consensus targets $21.95 (11 analysts), implying a -2.0% move over the next 12 months. The stock is currently 24% below its 52-week high of $29.35, remaining 14.9% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.70B↓ | $2.97B↑ | $2.83B↑ | $2.81B↑ | $2.63B |
| Gross Profit | $891.00M↑ | $577.00M↓ | $950.00M↓ | $991.00M↑ | $861.00M |
| Operating Income | $66.00M↑ | -$244.00M↓ | $172.00M↓ | $191.00M↑ | $58.00M |
| Net Income | -$15.00M↑ | -$1.13B↓ | -$46.00M↓ | $91.00M↓ | $126.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.82B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.85%
ROE
Average efficiency. Growth may require heavy reinvestment.
-18.17%
Volume
Today's trading volume
2.92M
Recent News
Will Baxter's Q2 Results Continue to Reflect Operational Headwinds?
BAX's second-quarter results may reflect pressured earnings and sales as manufacturing inefficiencies, inflation, and product holds offset steady demand across segments.
Earnings Preview: Baxter International (BAX) Q2 Earnings Expected to Decline
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
1 S&P 500 Stock for Long-Term Investors and 2 We Find Risky
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
3 Reasons to Avoid BAX and 1 Stock to Buy Instead
Baxter trades at $22.13 and has moved in lockstep with the market. Its shares have returned 10% over the last six months while the S&P 500 has gained 8.7%.
Why Abbott Stock Is Reimagining Its Future
Abbott’s (ABT) latest financial disclosure reveals a significant strategic evolution that market participants often overlook amidst the focus on quarterly beats. The company is actively executing a structural pivot, shifting its capital allocation and growth dependency away from the volatile Nutrition segment toward high-margin, innovation-led MedTech and specialized diagnostics.